Literature DB >> 20085502

Community acquired bacterial pneumonia.

Stavros Anevlavis1, Demosthenes Bouros.   

Abstract

IMPORTANCE OF THE FIELD: Community-acquired pneumonia (CAP) is a common and potentially life-threatening illness that continues to be a major medical problem. Among infectious diseases, CAP is the leading cause of death in the world and is associated with a substantial economic burden to health are systems around the globe. AREAS COVERED IN THIS REVIEW: Recently identified clinical and biochemical tools promise to improve the assessment of CAP severity. Various prognostic scoring systems and predictive biomarkers have been proposed as tools to aid clinicians in key management decisions. This review provides a summary of current evidence about the use of prognostic scoring systems and biomarkers in the management of patients presenting with CAP. According to the existing guidelines, until more accurate and rapid diagnostic methods are available, the initial treatment for most patients with CAP will remain empirical. Some novel antibiotic and nonantibiotic therapies have recently been tested; some empirical antimicrobial regimens are still being debated. This review summarizes the recent advances in the field of therapy and novel approaches. We searched PubMed for English-language references published from 1997 to 2009 using combinations of the following terms: 'community acquired pneumonia', 'community acquired bacterial pneumonia', 'therapy', 'antibiotics', 'antimicrobials', 'prognostic scoring systems', 'biomarkers', 'diagnostic testing', 'guidelines' 'etiological diagnosis'. WHAT THE READER WILL GAIN: A thorough description about recent advances in the field of therapy and novel approaches of CAP, as well as a summary of current evidence about the use of prognostic scoring systems and biomarkers in the management of patients presenting with CAP, is presented. TAKE HOME MESSAGE: Recent developments have made significant contributions to the management of CAP patients. However, various hot topics remain open and urgently require prospective studies in order to optimize the outcomes of CAP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20085502     DOI: 10.1517/14656560903508770

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  17 in total

1.  Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.

Authors:  Jr-Shiuan Lin; Frank M Szaba; Lawrence W Kummer; Brett A Chromy; Stephen T Smiley
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

2.  Secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting of multiple bacterial lung pathogens, a mouse model study.

Authors:  Jiangjiang Zhu; Heather D Bean; Jaime Jiménez-Díaz; Jane E Hill
Journal:  J Appl Physiol (1985)       Date:  2013-03-21

3.  Etiologic diagnosis of lower respiratory tract bacterial infections using sputum samples and quantitative loop-mediated isothermal amplification.

Authors:  Yu Kang; Rui Deng; Can Wang; Tao Deng; Peichao Peng; Xiaoxing Cheng; Guoqing Wang; Minping Qian; Huafang Gao; Bei Han; Yusheng Chen; Yinghui Hu; Rong Geng; Chengping Hu; Wei Zhang; Jingping Yang; Huanying Wan; Qin Yu; Liping Wei; Jiashu Li; Guizhen Tian; Qiuyue Wang; Ke Hu; Siqin Wang; Ruiqin Wang; Juan Du; Bei He; Jianjun Ma; Xiaoning Zhong; Lan Mu; Shaoxi Cai; Xiangdong Zhu; Wanli Xing; Jun Yu; Minghua Deng; Zhancheng Gao
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

4.  TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection.

Authors:  Frank M Szaba; Lawrence W Kummer; Debra K Duso; Ekaterina P Koroleva; Alexei V Tumanov; Andrea M Cooper; James B Bliska; Stephen T Smiley; Jr-Shiuan Lin
Journal:  PLoS Pathog       Date:  2014-05-22       Impact factor: 6.823

5.  Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia.

Authors:  Kelly R Reveles; Eric M Mortensen; Russell T Attridge; Christopher R Frei
Journal:  BMC Res Notes       Date:  2015-09-17

6.  A Year of Infection in the Intensive Care Unit: Prospective Whole Genome Sequencing of Bacterial Clinical Isolates Reveals Cryptic Transmissions and Novel Microbiota.

Authors:  David J Roach; Joshua N Burton; Choli Lee; Bethany Stackhouse; Susan M Butler-Wu; Brad T Cookson; Jay Shendure; Stephen J Salipante
Journal:  PLoS Genet       Date:  2015-07-31       Impact factor: 5.917

Review 7.  Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward.

Authors:  Joon Young Song; Byung Wook Eun; Moon H Nahm
Journal:  Infect Chemother       Date:  2013-12-27

8.  A pilot study on the diagnostic accuracy of proadrenomedullin and proatrial natriuretic Peptide in lower respiratory tract infections.

Authors:  Agustín Ruiz-González; Aureli Esquerda; José M Porcel; Silvia Bielsa; Horacio Valencia; Gonzalo Cao; Miquel Falguera
Journal:  Open Respir Med J       Date:  2014-06-27

9.  Adherence to therapeutic guidelines for patients with community-acquired pneumonia in Australian hospitals.

Authors:  Nr Adler; Hm Weber; I Gunadasa; Aj Hughes; Nd Friedman
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2014-09-14

10.  Retrospective cohort evaluation on risk of pneumonia in patients with pulmonary tuberculosis.

Authors:  Tsui-Ming Chang; Chih-Hsin Mou; Te-Chun Shen; Chien-Lung Yang; Min-Hui Yang; Fang-Yang Wu; Fung-Chang Sung
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.